Clinical trialNCT07059091RecruitingPhase 2Interventional

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

SponsorJohns Hopkins UniversityEnrollment334AllergiesChronic Obstructive Pulmonary Disease (COPD)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a follow-up call one month after your final clinic visit.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Elizabeth Sugar, PhD
Johns Hopkins University
Principal Investigator
clinicaltrials.gov ↗
Nirupama Putcha
Johns Hopkins School of Medicine
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama
Birmingham, Alabama, United States
Michael Wells
Not, yet, recruiting
University of Arizona- Tuscon
Tucson, Arizona, United States
Fernando Martinez →
Not, yet, recruiting
University of San Francisco
San Francisco, California, United States
Stephanie Christenson
Not, yet, recruiting
National Jewish Health
Denver, Colorado, United States
Barry Make
Not, yet, recruiting
University of Florida
Jacksonville, Florida, United States
Vandana Seeram
Not, yet, recruiting
Northwestern University
Chicago, Illinois, United States
Ravi Kalhan →
Not, yet, recruiting
Rush University Medical Center
Chicago, Illinois, United States
James Moy
Not, yet, recruiting
University of Illinois at Chicago
Chicago, Illinois, United States
Lynn Gerald
Not, yet, recruiting
University of Iowa
Iowa City, Iowa, United States
Alejandro Comellas
Not, yet, recruiting
University of Kansas Medical Center
Kansas City, Kansas, United States
Mario Castro →
Not, yet, recruiting
Johns Hopkins University
Baltimore, Maryland, United States
Niru Putcha
Recruiting
University of Michigan
Ann Arbor, Michigan, United States
MeiLan Han
Not, yet, recruiting
Henry Ford Health
Detroit, Michigan, United States
Alan Baptist
Not, yet, recruiting
Columbia University
New York, New York, United States
Emily DiMango
Not, yet, recruiting
Cornell University
New York, New York, United States
Robery Kaner
Not, yet, recruiting
Mount Sinai, Icahn School of Medicine
New York, New York, United States
Linda Rogers
Not, yet, recruiting
Duke University Medical Center
Durham, North Carolina, United States
Loretta Que
Not, yet, recruiting
Temple University
Philadelphia, Pennsylvania, United States
Nathaniel Marchetti →
Not, yet, recruiting
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Frank Sciurba
Not, yet, recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Katherine Cahill
Not, yet, recruiting
Baylor College of Medicine
Houston, Texas, United States
Nicola Hanania
Not, yet, recruiting
University of Vermont
Colchester, Vermont, United States
Anne Dixon
Not, yet, recruiting
Pacific Northwest Airways - Va Puget Sound Healthcare System, Seattle
Seattle, Washington, United States
Laura Freemster
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Omalizumab →Sodium chloride →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Feb 2026
Primary completion: 31 Jan 2031
Completion: 31 May 2031
Last update posted: 17 Feb 2026
Registered enrollment: 334
Registry id: NCT07059091

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.